Want to see PURE full AI Analyst Report?
PURE Stock Chart & Stats
$0.05
<$0.01(1.96%)
At close: 4:00 PM EST
$0.05
<$0.01(1.96%)
Day’s Range― - ―
52-Week Range$0.04 - $0.14
Previous CloseN/A
Volume1.63K
Average Volume (3M)53.72K
Market Cap
$8.15M
Enterprise Value$12.84M
Total Cash (Recent Filing)$983.00K
Total Debt (Recent Filing)$6.50M
Price to Earnings (P/E)―
Beta-0.74
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding130,017,560
10 Day Avg. Volume24,352
30 Day Avg. Volume53,720
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-1.96
Price to Sales (P/S)4.56
P/FCF Ratio>-0.01
Enterprise Value/Market Cap1.58
Enterprise Value/Revenue5.30
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda69.43
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Antimicrobial TechnologyPure Bioscience’s SDC (silver dihydrogen citrate) is a proprietary antimicrobial platform serving sanitation/disinfection markets. A defensible, application-specific technology can sustain product differentiation, enable recurring product sales to institutional customers, and support licensing or channel partnerships over the medium term.
Sustained Revenue RecoveryThe company’s ~62% TTM revenue growth and multi-year rebound indicate improving commercial traction and demand for SDC-enabled products. Durable top-line expansion supports scale opportunities, helps amortize fixed costs, and provides a structural basis for future margin improvement if cost structure and mix are managed.
Insider-backed Financing Improved LiquidityThe $1.0M private placement, with board participation, strengthens near-term liquidity and signals insider alignment. Additional runway helps sustain R&D, regulatory or sales initiatives and reduces immediate solvency pressure, preserving the firm’s ability to execute on strategic initiatives while seeking longer-term funding.
Bears Say
Fragile Balance Sheet / Negative EquityNegative shareholders’ equity reflects accumulated losses and a weakened capital base, constraining the company’s ability to absorb shocks. Over the medium term this raises refinancing and covenant risks, limits capacity for investments, and makes raising non-dilutive capital or credit more difficult and costly.
Persistent Negative Cash GenerationConsistent negative operating and free cash flow (TTM cash burn ~-$1.8M) shows the core business does not self-fund. Reliance on external financing to sustain operations is structural risk: repeated raises dilute shareholders, stress management focus on liquidity, and create execution risk if capital access tightens.
Profitability And Reporting AnomaliesThe combination of persistent losses and noted anomalies in reported gross profit reduces confidence in financial metrics. This undermines forecasting, heightens due diligence for partners/lenders, and raises execution risk: if margins are overstated or volatile, planned scaling and financing assumptions may prove unreliable.
Pure Bioscience News
PURE FAQ
What was Pure Bioscience’s price range in the past 12 months?
Pure Bioscience lowest stock price was $0.04 and its highest was $0.14 in the past 12 months.
What is Pure Bioscience’s market cap?
Pure Bioscience’s market cap is $8.15M.
When is Pure Bioscience’s upcoming earnings report date?
Pure Bioscience’s upcoming earnings report date is Nov 03, 2026 which is in 113 days.
How were Pure Bioscience’s earnings last quarter?
Pure Bioscience released its earnings results on Jun 15, 2026. The company reported -$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.006.
Is Pure Bioscience overvalued?
According to Wall Street analysts Pure Bioscience’s price is currently Overvalued.
Does Pure Bioscience pay dividends?
Pure Bioscience does not currently pay dividends.
What is Pure Bioscience’s EPS estimate?
Pure Bioscience’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pure Bioscience have?
Pure Bioscience has 130,017,560 shares outstanding.
What happened to Pure Bioscience’s price movement after its last earnings report?
Pure Bioscience reported an EPS of -$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.857%.
Which hedge fund is a major shareholder of Pure Bioscience?
Currently, no hedge funds are holding shares in PURE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pure Bioscience
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company’s technology platform contains silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a ready-to-use hard surface disinfectant and food contact surface sanitizer and disinfectant; PURE Control, eliminates pathogens in produce, such as salmonella, e. coli, and listeria; PURE Multi-Purpose Hi-Foam Floor Cleaner Concentrate, a cleaning product for stainless steel, floors, walls, and painted areas; PURE Multi-Purpose Floor Cleaner, for sanitation in food processing plants, commercial kitchens, healthcare facilities, schools, and hospitality settings; and SILVERION, a SDC-based antimicrobial formulation for use as a raw material ingredient in the manufacturing of personal care products. The company serves food processing, food service and hospitality, healthcare, facility care, transportation, and personal care industries. It sells its products through end-use customers and third-party distributors. The company was incorporated in 1992 and is based in El Cajon, California.
Technical Analysis
Mannatech
―
United-Guardian
―
Tantech Holdings
―
Grove Collaborative Holdings
―
Yoshitsu Co. Ltd. Sponsored ADR
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.62% Other Institutional Investors
99.38% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---